ATE435238T1 - Herstellung eines einkettigen fv antikörperfragments - Google Patents
Herstellung eines einkettigen fv antikörperfragmentsInfo
- Publication number
- ATE435238T1 ATE435238T1 AT04010702T AT04010702T ATE435238T1 AT E435238 T1 ATE435238 T1 AT E435238T1 AT 04010702 T AT04010702 T AT 04010702T AT 04010702 T AT04010702 T AT 04010702T AT E435238 T1 ATE435238 T1 AT E435238T1
- Authority
- AT
- Austria
- Prior art keywords
- preparation
- antibody fragment
- single chain
- methods
- antibody fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04010702A EP1593690B1 (de) | 2004-05-05 | 2004-05-05 | Herstellung eines einkettigen fv Antikörperfragments |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE435238T1 true ATE435238T1 (de) | 2009-07-15 |
Family
ID=34924877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04010702T ATE435238T1 (de) | 2004-05-05 | 2004-05-05 | Herstellung eines einkettigen fv antikörperfragments |
Country Status (8)
Country | Link |
---|---|
US (2) | US8247194B2 (de) |
EP (2) | EP1593690B1 (de) |
AT (1) | ATE435238T1 (de) |
AU (1) | AU2005238203B2 (de) |
CA (1) | CA2562604C (de) |
DE (1) | DE602004021773D1 (de) |
DK (1) | DK1593690T3 (de) |
WO (1) | WO2005105844A2 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1593690B1 (de) * | 2004-05-05 | 2009-07-01 | Micromet AG | Herstellung eines einkettigen fv Antikörperfragments |
RU2458071C2 (ru) | 2005-04-18 | 2012-08-10 | Микромет Аг | Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека |
HUE058876T2 (hu) | 2005-05-18 | 2022-09-28 | Morphosys Ag | Anti-GM-CSF antitestek és felhasználásuk |
JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
AU2013201228B2 (en) * | 2006-02-08 | 2016-01-21 | Eisai, Inc. | Antigenic gm-csf peptides and antibodies to gm-csf |
CN101501070B (zh) * | 2006-02-08 | 2013-12-25 | 诺福泰克公司 | 抗原性gm-csf肽和针对gm-csf的抗体 |
US8232372B2 (en) * | 2006-12-14 | 2012-07-31 | Schering Corp. | Engineered anti-TSLP antibody |
TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
MX2010005291A (es) | 2007-11-13 | 2010-11-12 | Evec Inc | Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos. |
US8840890B2 (en) * | 2008-11-12 | 2014-09-23 | University Of Maryland, Baltimore | Rapid expression cloning of human monoclonal antibodies from memory B cells |
EP3381471B1 (de) | 2008-12-22 | 2024-03-20 | The University of Melbourne | Schmerzbehandlung |
RU2712273C2 (ru) | 2008-12-22 | 2020-01-28 | Де Юниверсити Оф Мельбурн | Лечение остеоартрита |
KR101898739B1 (ko) | 2009-11-04 | 2018-09-13 | 머크 샤프 앤드 돔 코포레이션 | 조작된 항-tslp 항체 |
US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
EP2914289B1 (de) | 2012-10-31 | 2019-05-22 | Takeda GmbH | Lyophilisierte formulierung mit einer gm-csf-neutralisierenden verbindung |
AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
CN118178647A (zh) | 2013-08-30 | 2024-06-14 | 武田药品工业株式会社 | 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体 |
CN106661119A (zh) | 2014-07-01 | 2017-05-10 | 辉瑞公司 | 双特异性异二聚化双抗体及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265150B1 (en) * | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
EP1593690B1 (de) * | 2004-05-05 | 2009-07-01 | Micromet AG | Herstellung eines einkettigen fv Antikörperfragments |
-
2004
- 2004-05-05 EP EP04010702A patent/EP1593690B1/de not_active Expired - Lifetime
- 2004-05-05 AT AT04010702T patent/ATE435238T1/de active
- 2004-05-05 DE DE602004021773T patent/DE602004021773D1/de not_active Expired - Lifetime
- 2004-05-05 DK DK04010702T patent/DK1593690T3/da active
-
2005
- 2005-05-04 CA CA2562604A patent/CA2562604C/en active Active
- 2005-05-04 AU AU2005238203A patent/AU2005238203B2/en active Active
- 2005-05-04 WO PCT/EP2005/004893 patent/WO2005105844A2/en active Application Filing
- 2005-05-04 US US11/568,685 patent/US8247194B2/en active Active
- 2005-05-04 EP EP05743231A patent/EP1742967A2/de not_active Withdrawn
-
2012
- 2012-08-17 US US13/588,678 patent/US9279017B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1593690A1 (de) | 2005-11-09 |
US8247194B2 (en) | 2012-08-21 |
CA2562604A1 (en) | 2005-11-10 |
DE602004021773D1 (de) | 2009-08-13 |
AU2005238203A1 (en) | 2005-11-10 |
WO2005105844A3 (en) | 2006-01-26 |
AU2005238203B2 (en) | 2010-09-02 |
CA2562604C (en) | 2014-02-18 |
EP1742967A2 (de) | 2007-01-17 |
WO2005105844A2 (en) | 2005-11-10 |
US20080193978A1 (en) | 2008-08-14 |
US9279017B2 (en) | 2016-03-08 |
US20130171165A1 (en) | 2013-07-04 |
EP1593690B1 (de) | 2009-07-01 |
DK1593690T3 (da) | 2009-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE435238T1 (de) | Herstellung eines einkettigen fv antikörperfragments | |
NL300911I2 (nl) | sarilumab | |
WO2008097817A3 (en) | Multivariable antigens complexed with targeting humanized monoclonal antibody | |
NO2017032I1 (no) | bezlotoksumab | |
ATE452147T1 (de) | Antikörper mit korrigierten cdr | |
WO2005069970A3 (en) | Antibody specificity transfer using minimal essential binding determinants | |
CR20150102A (es) | Anticuerpos que se unen a il-4 y/o il-13 (divisional 2) | |
WO2007137984A3 (en) | Modified humanised anti-interleukin-18 antibodies | |
NZ607711A (en) | Antibodies directed to her-3 and uses thereof | |
EP1912674B8 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
BRPI0908508A2 (pt) | anticorpo monoclonal nkg2a anti-humano humanizado | |
NZ623706A (en) | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof | |
IL197459A0 (en) | Humanized proteins, including antibodies and methods for producing the same | |
EP2162469A4 (de) | Neue verfahren zur humanisierung von kaninchenantikörpern und humanisierte kaninchenantikörper | |
ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
WO2007063415A3 (en) | Methods of producing stable b-lymphocytes | |
BRPI0509495A2 (pt) | anticorpo humanizado | |
WO2008052108A3 (en) | Methods for use in human-adapting monoclonal antibodies | |
WO2011112850A3 (en) | Humanized and chimeric anti-properdin antibodies | |
NZ594668A (en) | Humanised antibodies with anti-tumour activity | |
NZ607881A (en) | Humanized antibody against amyloid beta | |
WO2008068359A3 (es) | Método para producir anticuerpos mediante inmunización con haptenos unidos a partículas de óxidos metálicos | |
NZ708488A (en) | Method of providing disease-specific binding molecules and targets | |
AU2004902842A0 (en) | Monoclonal antibody against ABCA1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1593690 Country of ref document: EP |
|
UEP | Publication of translation of european patent specification |
Ref document number: 1593690 Country of ref document: EP |